Diagonal Bio AB (publ) (NGM:DIABIO)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.0130
0.00 (0.00%)
At close: May 13, 2025
-86.02%
Market Cap 15.79M
Revenue (ttm) 1.13M
Net Income (ttm) -9.93M
Shares Out 1.21B
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,080,538
Average Volume 7,311,487
Open n/a
Previous Close 0.0130
Day's Range n/a
52-Week Range 0.0063 - 0.0959
Beta -1.83
RSI 42.69
Earnings Date May 14, 2025

About Diagonal Bio AB

Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was inco... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 5
Stock Exchange Nordic Growth Market
Ticker Symbol DIABIO
Full Company Profile

Financial Performance

In 2024, Diagonal Bio AB's revenue was 1.13 million, a decrease of -64.30% compared to the previous year's 3.15 million. Losses were -9.93 million, -14.97% less than in 2023.

Financial Statements

News

There is no news available yet.